Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 7Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy 1NSCLC 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Cervical Cancer Metastatic 1Carcinoma, Transitional Cell 1BRCA-Mutated Breast Carcinoma 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

Radiotherapy 4Immune Checkpoint Inhibitors 4famitinib 1camrelizumab 1aflutinib 1Oxaliplatin 1Nivolumab 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced NSCLC × famitinib × Clear all
NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
1 enrolled
Thoracic

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡